Poolbeg Pharma granted US patent related to influenza drug

Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive. Skillington compared the potential of Poolbeg to that of Amryt Pharma, which was sold to Chiesi Farmaceutici for $1.48

Background Cytokine Release Syndrome (CRS) is a well-recognized toxicity that occurs with high frequency following treatments such as T-cell engaging antibodies, Chimeric Antigen Receptor (CAR) T cells and other T-cell boosting immunotherapies. In addition to patient mortality and

Artificial intelligence (AI) has emerged as a promising solution with significant potential to revolutionize drug discovery and development. The global AI in healthcare market, valued at USD 16.3 billion in 2022, is projected to grow at a CAGR

Artificial Intelligence (AI) has emerged as a transformative force in various industries, and the field of drug discovery is no exception. AI-powered technologies have revolutionized the way pharmaceutical research is conducted, accelerating the discovery and development of new

Poolbeg Pharma (AIM: POLB) has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi. These experienced professionals will assume pivotal roles within

Artificial intelligence (AI) and machine learning (ML) technologies are redefining the way biopharma companies discover and develop drugs. It’s not a passing phase, either. Half of the 50 biggest pharmaceutical companies have entered into partnerships or licensing agreements with AI companies

Poolbeg Pharma announced the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise and capabilities. Poolbeg’s Chairman, Cathal Friel, co-founded both

Three members of Irish-based Amryt Pharma’s former leadership team are set to assume “pivotal roles” at London-headquartered pharma and biotech firm Poolbeg Pharma. David Allmond, John McEvoy and Laura Maher will join the company in the coming months. Allmond will become chief business officer

The discove­ry of new drugs has always been a challe­nging and expensive proce­ss. It involves extensive­ timeframes and significant costs, which have long highlighte­d the need for re­form in this critical field. Despite pre­vious efforts to accelerate drug

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has signed a strategic collaboration agreement with a Nasdaq-listed biopharma company for the development of an optimised oral drug to

Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a strategic collaboration agreement with a Nasdaq listed biopharma company for the development of an optimised oral drug to treat

The COVID-19 pandemic was an eye opener for the world on how quickly diseases and pathogens can emerge and spread globally, wreaking havoc on societies, economies, and healthcare systems. While the pharmaceutical industry scrambled for vaccines and treatments

Poolbeg Pharma has partnered with a Nasdaq-listed biopharma company on its oral delivery platform. The strategic collaboration will see both companies develop an optimised oral drug to treat a metabolic condition. Poolbeg said that it will receive funding